NCT00835536View on ClinicalTrials.gov

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Healthy
Interventions
DRUG

Ribavirin 200 mg tablets

1 x 200 mg, single-dose non-fasting

DRUG

COPEGUS™ 200 mg Tablets

1 x 200 mg, single-dose non-fasting

Trial Locations (2)

77042

Novum Pharmaceutical Research Services, Houston

77099

Bioassay Laboratory, Inc., Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00835536 - Ribavirin 200 mg Tablets Under Non-Fasting Conditions | Biotech Hunter | Biotech Hunter